Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsirigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohashi PS, Brooks DG, McGaha TL.

Sci Immunol. 2019 Dec 13;4(42). pii: eaax8189. doi: 10.1126/sciimmunol.aax8189.

PMID:
31836669
2.

Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.

Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, Paiella S, Salvia R, De Sanctis F, Poffe O, Anselmi C, Hofer F, Sartoris S, Piro G, Carbone C, Corbo V, Lawlor R, Solito S, Pinton L, Mandruzzato S, Bassi C, Scarpa A, Bronte V, Ugel S.

J Immunother Cancer. 2019 Sep 18;7(1):255. doi: 10.1186/s40425-019-0734-6.

3.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

4.

The Endless Saga of Monocyte Diversity.

Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, Bronte V.

Front Immunol. 2019 Aug 6;10:1786. doi: 10.3389/fimmu.2019.01786. eCollection 2019. Review.

5.

Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease.

Filippini D, Agosto S, Delfino P, Simbolo M, Piro G, Rusev B, Veghini L, Cantù C, Lupo F, Ugel S, De Sanctis F, Bronte V, Milella M, Tortora G, Scarpa A, Carbone C, Corbo V.

Sci Rep. 2019 Aug 22;9(1):12286. doi: 10.1038/s41598-019-48663-7.

6.

Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report.

Bertelli G, Trovato R, Ugel S, Bria E, Milella M, Bronte V, Pilotto S.

Clin Lung Cancer. 2019 Jul;20(4):e514-e516. doi: 10.1016/j.cllc.2019.04.013. Epub 2019 Apr 28. No abstract available.

PMID:
31122866
7.

Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells.

Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, Pressiani T, Mazzone M, Trovato R, Ugel S, Bronte V, Tripodo C, Colombo MP, Genazzani AA, Sica A.

Cancer Res. 2019 Apr 15;79(8):1938-1951. doi: 10.1158/0008-5472.CAN-18-1544. Epub 2019 Feb 18.

PMID:
30777853
8.

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes.

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V.

Nat Commun. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.

9.

Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo.

Solito S, Pinton L, De Sanctis F, Ugel S, Bronte V, Mandruzzato S, Marigo I.

Curr Protoc Immunol. 2019 Feb;124(1):e61. doi: 10.1002/cpim.61. Epub 2018 Oct 10.

PMID:
30303619
10.

Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound.

Dugnani E, Pasquale V, Marra P, Liberati D, Canu T, Perani L, De Sanctis F, Ugel S, Invernizzi F, Citro A, Venturini M, Doglioni C, Esposito A, Piemonti L.

Carcinogenesis. 2018 Sep 21;39(9):1197-1206. doi: 10.1093/carcin/bgy094.

PMID:
30052815
11.

T-cell tracking using Cerenkov and radioluminescence imaging.

Boschi F, De Sanctis F, Ugel S, Spinelli AE.

J Biophotonics. 2018 Oct;11(10):e201800093. doi: 10.1002/jbio.201800093. Epub 2018 Jul 5.

PMID:
29770603
12.

Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.

De Sanctis F, Sandri S, Martini M, Mazzocco M, Fiore A, Trovato R, Garetto S, Brusa D, Ugel S, Sartoris S.

Vaccine. 2018 Jun 14;36(25):3708-3716. doi: 10.1016/j.vaccine.2018.05.010. Epub 2018 May 8.

PMID:
29752021
13.

The dark side of tumor-associated endothelial cells.

De Sanctis F, Ugel S, Facciponte J, Facciabene A.

Semin Immunol. 2018 Feb;35:35-47. doi: 10.1016/j.smim.2018.02.002. Epub 2018 Feb 26. Review.

PMID:
29490888
14.

Anti-telomerase T cells adoptive transfer.

De Sanctis F, Trovato R, Ugel S.

Aging (Albany NY). 2017 Nov 30;9(11):2239-2240. doi: 10.18632/aging.101336. No abstract available.

15.

Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.

Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S.

Oncotarget. 2017 May 23;8(50):86987-87001. doi: 10.18632/oncotarget.18115. eCollection 2017 Oct 20.

16.

Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients.

Giardino A, Innamorati G, Ugel S, Perbellini O, Girelli R, Frigerio I, Regi P, Scopelliti F, Butturini G, Paiella S, Bacchion M, Bassi C.

Pancreatology. 2017 Nov - Dec;17(6):962-966. doi: 10.1016/j.pan.2017.09.008. Epub 2017 Sep 27.

PMID:
29037917
17.

The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO.

Mondanelli G, Ugel S, Grohmann U, Bronte V.

Curr Opin Pharmacol. 2017 Aug;35:30-39. doi: 10.1016/j.coph.2017.05.002. Epub 2017 May 26. Review.

PMID:
28554057
18.

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.

Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, Bronte V, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EMC, Bicciato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U.

Immunity. 2017 Feb 21;46(2):233-244. doi: 10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14.

19.

Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53.

Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, Adamo A, Krampera M, Scupoli MT, Croce CM, Scarpa A.

Oncotarget. 2017 Feb 14;8(7):11809-11826. doi: 10.18632/oncotarget.14683.

20.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

21.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

22.

Tumor-Induced Myeloid-Derived Suppressor Cells.

De Sanctis F, Bronte V, Ugel S.

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.MCHD-0016-2015. Review.

PMID:
27337449
23.

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.

Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S.

Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318.

24.

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Ugel S, De Sanctis F, Mandruzzato S, Bronte V.

J Clin Invest. 2015 Sep;125(9):3365-76. doi: 10.1172/JCI80006. Epub 2015 Sep 1. Review.

25.

Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.

Ugel S, Facciponte JG, De Sanctis F, Facciabene A.

Cancer Immunol Immunother. 2015 Oct;64(10):1339-48. doi: 10.1007/s00262-015-1747-8. Epub 2015 Aug 13. Review.

PMID:
26267042
26.

MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I.

Biochim Biophys Acta. 2016 Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. Review.

PMID:
26255541
27.

Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, Bronte V, Sartoris S.

Immunology. 2015 Sep;146(1):33-49. doi: 10.1111/imm.12477. Epub 2015 Jun 15.

28.

Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models.

Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, Bronte V, Boggi U, Campani D, Funel N, Moroni L, Danti S.

Biomatter. 2014;4:e955386. doi: 10.4161/21592527.2014.955386.

29.

Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A.

J Clin Invest. 2014 Apr;124(4):1497-511. doi: 10.1172/JCI67382. Epub 2014 Mar 18.

30.

The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, Bronte V.

Front Immunol. 2014 Feb 24;5:69. doi: 10.3389/fimmu.2014.00069. eCollection 2014. Review.

31.

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V.

Cell Rep. 2012 Sep 27;2(3):628-39. doi: 10.1016/j.celrep.2012.08.006. Epub 2012 Sep 6.

32.

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A, Bronte V, Viola A.

J Exp Med. 2011 Sep 26;208(10):1949-62. doi: 10.1084/jem.20101956. Epub 2011 Sep 19.

33.

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V.

Immunity. 2010 Jun 25;32(6):790-802. doi: 10.1016/j.immuni.2010.05.010. Epub 2010 Jun 3.

34.

IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.

Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S.

Vaccine. 2010 Apr 30;28(20):3548-57. doi: 10.1016/j.vaccine.2010.03.007. Epub 2010 Mar 19.

PMID:
20304037
35.

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V.

Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903.

36.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

37.

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.

Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V.

Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.

PMID:
19903903
38.

Therapeutic targeting of myeloid-derived suppressor cells.

Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V.

Curr Opin Pharmacol. 2009 Aug;9(4):470-81. doi: 10.1016/j.coph.2009.06.014. Epub 2009 Jul 16. Review.

PMID:
19616475
39.

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.

Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini T, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, Bronte V, Scarselli E.

Cancer Res. 2008 Dec 1;68(23):9865-74. doi: 10.1158/0008-5472.CAN-08-1603.

40.

Role of arginine metabolism in immunity and immunopathology.

Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, Bronte V, Zanovello P.

Immunobiology. 2007;212(9-10):795-812. Epub 2007 Nov 14. Review.

PMID:
18086380
41.

Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.

Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P.

Immunol Invest. 2006;35(3-4):327-57. Review.

PMID:
16916757

Supplemental Content

Support Center